Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01453413 · ClinicalTrials.gov registry record · NA

Blood Glucose Testing and You

A NA study, sponsored by Ascensia Diabetes Care.

Completed
Registry status
NA
Development phase
297
Enrollment target

NCT01453413: Completed NA study, sponsored by Ascensia Diabetes Care.

NCT01453413 is a NA study that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 297 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01453413, a NA study, has completed, sponsored by Ascensia Diabetes Care.

COMPLETED
Registry status
NA
Development phase
297 participants
Enrollment target

Study Summary

The purpose of this study is to determine the difference between self-reported, estimated blood glucose level versus blood glucose levels measured with a Blood Glucose Meter.

Primary Outcome

The percent of subjects whose estimated blood glucose values are different than meter BG values. A calculation was performed to determine the percent of subjects whose estimated BG values are \> +/-20% different than meter BG values when samples have BG \>=75mg/dL or \> +/- 15mg/dL different than meter BG values when samples have BG \<75mg/dL, as measured by fingerstick CONTOUR®.

Interventions

  • OTHER Blood Glucose meter

Trial Details

FieldValue
Enrollment Target 297 participants
Start Date 2011-10
Est. Completion 2011-11
Phase NA
Ascensia Diabetes Care

42 total trials

What the finished NCT01453413 record still lists

NCT01453413 is an interventional study that assigns participants to a tested intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 1 intervention - of which Blood Glucose meter is the first listed.

NCT01453413 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01453413 about?

NCT01453413 is a clinical study titled "Blood Glucose Testing and You". The purpose of this study is to determine the difference between self-reported, estimated blood glucose level versus blood glucose levels measured with a Blood Glucose Meter.

What is the current status of trial NCT01453413?

This trial is currently completed. It is a NA study. The enrollment target is 297 participants. The study started on 2011-10. Estimated completion is 2011-11.

What interventions are being tested in trial NCT01453413?

The interventions under investigation include: Blood Glucose meter (OTHER).

Who is sponsoring clinical trial NCT01453413?

This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01453413's enrollment target sits among peer trials

297 372nd of 2000 higher than 1,628 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06309160 · 297 participants · NA

    COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD

  • NCT06375811 · 297 participants · Phase 3

    Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

  • NCT07222215 · 297 participants · Phase 2

    PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

  • NCT06305624 · 298 participants · NA

    Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01453413, the US trial registry maintained by the National Library of Medicine. NCT01453413 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.